Spyre Therapeutics (SYRE) Accumulated Depreciation (2015 - 2022)

Spyre Therapeutics (SYRE) has 8 years of Accumulated Depreciation data on file, last reported at $4.1 million in Q4 2022.

• For the quarter ending Q4 2022, Accumulated Depreciation rose 47.89% year-over-year to $4.1 million; the trailing twelve-month figure through Dec 2022 stood at $4.1 million (up 47.89% YoY), and the FY2022 full-year result was $4.1 million, up 47.89% from the prior year.
• Accumulated Depreciation for Q4 2022 stood at $4.1 million, up from $2.8 million in the prior quarter.
• Across five years, Accumulated Depreciation topped out at $4.1 million in Q4 2022 and bottomed at $752000.0 in Q4 2018.
• The 5-year median for Accumulated Depreciation is $2.0 million (2020), against an average of $2.1 million.
• The widest annual swing landed in 2019, when Accumulated Depreciation jumped 40.29%; it then jumped 87.96% in 2020.
• A 5-year view of Accumulated Depreciation shows it stood at $752000.0 in 2018, then soared by 40.29% to $1.1 million in 2019, then surged by 87.96% to $2.0 million in 2020, then surged by 41.3% to $2.8 million in 2021, then jumped by 47.89% to $4.1 million in 2022.
• The last three Accumulated Depreciation figures came in at $4.1 million (Q4 2022), $2.8 million (Q4 2021), and $2.0 million (Q4 2020), per Business Quant data.

Peer Comparison